Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

ABSTRACT:

Purpose

Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.

Methods

Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORR_Wk24); secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Tumor assessments were evaluated by investigators per immune-related RECIST.

Results

At data cutoff, 108 patients with previously treate

SUBMITTER: Makker V 

PROVIDER: S-EPMC7479759 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature